Since preclinical studies of FGF21 actions on liver steatosis were previously conducted only in males, more studies are needed to evaluate the efficacy of FGF21 in improving glucose metabolism and NAFLD in obese females. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.